



## Current Insights and Future Perspectives into Signaling Pathways and Mechanisms of Drug Resistance in Cancer

Guest Editor:

**Dr. Ranjana Kanchan**

College of Medicine, University of  
Nebraska Medical Center,  
Omaha, NE 68198, USA

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editor

Cancer is a common disease responsible for a significant proportion of human mortality, with there being over 200 types of cancers. The high death rate in cancer patients is due to delayed diagnosis and the lack of standard and effective treatment. This Special Issue, “Current Insights and Future Perspectives into Signaling Pathways and Mechanisms of Drug Resistance in Cancer”, focuses on the roles of these pathways in drug resistance to anticancer agents.

In this Special Issue, both original research articles and reviews are welcome. Submissions can cover any relevant topic, including the current and future perspectives of targeting EGFR, PI3K/Akt/mTOR, Wnt,  $\beta$ -Catenin, TGF- $\beta$ , and Notch signaling pathways; redox-related pathways; and the epigenetic change-mediated reprogramming of cell signaling to overcome drug resistance.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)